Sanofi wins FDA TB nod; UCB brings on Daiichi to market Vimpat in Japan;

> Sanofi ($SNY) has won FDA approval for Priftin tablets to treat latent tuberculosis infection. Release (PDF)

> Daiichi Sankyo has teamed up with UCB to commercialize epilepsy treatment Vimpat in Japan. Report

> Ranbaxy and Epirus have launched a biosimilar of Johnson & Johnson's ($JNJ) Remicade in India. More

> The EU has greenlighted Astellas' Xtandi for prechemo prostate cancer. Report

> Otsuka says new pickup Avanir's ($AVNR) sales and marketing capabilities can help it create a global CNS company. Release

And Finally... GlaxoSmithKline ($GSK) has named the winners for its drug-hunter challenge. More

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.